Traders should monitor for follow-up announcements post-AACR presentation, including potential partnership talks or research expansions. This proof-of-concept strengthens Evaxion’s platform narrative, which may re-rate the stock if commercial interest materializes.
Price Chart
Executive Summary
Evaxion announced new data from a collaboration with Duke University showing its AI-Immunology™ platform can identify endogenous retrovirus (ERV)-derived antigens for use in personalized vaccines for glioblastoma, a deadly brain cancer with limited treatment options. The findings, to be presented at AACR 2026, demonstrate a novel antigen source that could improve vaccine efficacy in low mutational burden cancers.
Key Facts
- AI-Immunology™ platform identified ERV-derived antigens in glioblastoma tumor samples, a novel target source absent in normal tissue.
- Data shows feasibility of including both ERV antigens and neoantigens in personalized vaccines for most glioblastoma patients.
- Immunologic responses to ERV antigens were experimentally confirmed, supporting clinical potential.
- Results to be presented at AACR Annual Meeting on April 22, 2026, increasing scientific visibility.
- Glioblastoma has low mutational burden and few neoantigens, making this new antigen source highly significant.
Financial Impact
Non-dilutive scientific validation with potential to increase partnership and licensing interest; no immediate revenue impact but enhances platform valuation.
Risk Factors
- Clinical application remains preclinical; no guarantee of therapeutic success in humans.
- High market expectations could lead to sell-off if AACR data underwhelms or lacks robustness.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access